Search Results - "Khan, Naeem D"

Difference in Medication Adherence Between Patients Prescribed a 30-Day Versus 90-Day Supply After Acute Myocardial Infarction by Rymer, Jennifer A, Fonseca, Eileen, Bhandary, Durgesh D, Kumar, Deepa, Khan, Naeem D, Wang, Tracy Y

“…Background Evidence-based medication adherence rates after a myocardial infarction are low. We hypothesized that 90-day prescriptions are underused and may…”
Get full text

Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention by Sweeny, Joseph M, Angiolillo, Dominick J, Franchi, Francesco, Rollini, Fabiana, Waksman, Ron, Raveendran, Ganesh, Dangas, George, Khan, Naeem D, Carlson, Glenn F, Zhao, Yonggang, Teng, Renli, Mehran, Roxana

“…Diabetes mellitus (DM) is associated with enhanced platelet reactivity and impaired response to oral antiplatelet therapy, including clopidogrel. This post hoc…”
Get full text

Effect of Medication Co-payment Vouchers on P2Y12 Inhibitor Use and Major Adverse Cardiovascular Events Among Patients With Myocardial Infarction: The ARTEMIS Randomized Clinical Trial by Wang, Tracy Y, Kaltenbach, Lisa A, Cannon, Christopher P, Fonarow, Gregg C, Choudhry, Niteesh K, Henry, Timothy D, Cohen, David J, Bhandary, Durgesh, Khan, Naeem D, Anstrom, Kevin J, Peterson, Eric D

“…IMPORTANCE: Despite guideline recommendations, many patients discontinue P2Y12 inhibitor therapy earlier than the recommended 1 year after myocardial…”
Get full text

New Heart Failure After Myocardial Infarction (From the National Cardiovascular Data Registries [NCDR] Linked With All-Payer Claims) by Faridi, Kamil F., Bhalla, Narinder, Atreja, Nipun, Venditto, John, Khan, Naeem D., Wilson, Thomas, Fonseca, Eileen, Shen, Changyu, Yeh, Robert W., Secemsky, Eric A.

“…•After MI, 18.8% of patients develop new HF within 5 years after discharge.•CKD and recurrent MI are the strongest risk factors for new HF after MI.•A simple…”
Get full text

Pharmacokinetics and pharmacodynamics of ticagrelor in subjects on hemodialysis and subjects with normal renal function by Teng, Renli, Muldowney, Sharen, Zhao, Yonggang, Berg, Jolene Kay, Lu, Jonathan, Khan, Naeem D.

“…Purpose This single-dose, randomized, open-label, parallel-group, and crossover study assessed pharmacokinetics (PK), pharmacodynamics (PD), and safety of…”
Get full text

Translating clinical evidence into value-based payment models: pooled analyses of innovative real-world outcomes agreements for ticagrelor in the United States by Bhandary, Durgesh, Atreja, Nipun, Belletti, Daniel A, Bhalla, Narinder, Khan, Naeem D, Cobden, David S

“…Innovative value strategies for reimbursement of medications include value-based agreements (VBAs) between payers and pharmaceutical manufacturers, which have…”
Get full text

Hospitalization for Myocardial Infarction with Ticagrelor or Clopidogrel in Patients with Acute Coronary Syndrome: An On-Treatment Comparative Effectiveness Analysis by Olufade, Tope, Atreja, Nipun, Bhalla, Narinder, Venditto, John, Bhandary, Durgesh, Chafekar, Kaushik, Cobden, David, Khan, Naeem D.

“…Introduction Prescribing patterns and suboptimal adherence present methodological challenges for real-world head-to-head comparisons of ticagrelor and…”
Get full text

Contemporary Predictors of Major Adverse Cardiovascular Events Following Percutaneous Coronary Intervention: A Nationally Representative US Sample by Horne, Benjamin D, Atreja, Nipun, Venditto, John, Wilson, Thomas, Muhlestein, Joseph B, St Clair, Joshua R, Knowlton, Kirk U, Khan, Naeem D, Bhalla, Narinder, Anderson, Jeffrey L

“…: Patient outcomes after percutaneous coronary intervention (PCI) have improved over the last 30 years due to better techniques, therapies, and care processes…”
Get full text

Outcomes of Medicare beneficiaries hospitalised with transient ischaemic attack and stratification using the ABCD 2 score by Shah, Shreyansh, Liang, Li, Bhandary, Durgesh, Johansson, Saga, Smith, Eric E, Bhatt, Deepak L, Fonarow, Gregg C, Khan, Naeem D, Peterson, Eric, Bettger, Janet Prvu

“…Long-term outcomes for Medicare beneficiaries hospitalised with transient ischaemic attack (TIA) and role of ABCD score in identifying high-risk individuals…”
Get full text

Ticagrelor in Peripheral Artery Disease Endovascular Revascularization (TI-PAD): Challenges in clinical trial execution by Rogers, R Kevin, Hiatt, William R, Patel, Manesh R, Shishehbor, Mehdi H, White, Robin, Khan, Naeem D, Bhalla, Narinder P, Jones, W Schuyler, Low Wang, Cecilia C

“…There is limited evidence to guide clinical decision-making for antiplatelet therapy in peripheral artery disease (PAD) in the setting of lower extremity…”
Get full text

Addressing Therapeutic Inertia in 2020 and Beyond: A 3-Year Initiative of the American Diabetes Association by Gabbay, Robert A, Kendall, Debbie, Beebe, Christine, Cuddeback, John, Hobbs, Todd, Khan, Naeem D, Leal, Sandra, Miller, Eden, Novak, Lucia M, Rajpathak, Swapnil N, Scribner, Paul, Meneghini, Luigi, Khunti, Kamlesh

“…Research has shown that getting to glycemic targets early on leads to better outcomes in people with type 2 diabetes; yet, there has been no improvement in the…”
Get full text

Agreement and Accuracy of Medication Persistence Identified by Patient Self-report vs Pharmacy Fill: A Secondary Analysis of the Cluster Randomized ARTEMIS Trial by Fanaroff, Alexander C, Peterson, Eric D, Kaltenbach, Lisa A, Cannon, Christopher P, Choudhry, Niteesh K, Henry, Timothy D, Anstrom, Kevin J, Cohen, David J, Fonseca, Eileen, Khan, Naeem D, Fonarow, Gregg C, Wang, Tracy Y

“…Pharmacy fill data are increasingly accessible to clinicians and researchers to evaluate longitudinal medication persistence beyond patient self-report. To…”
Get more information

Outcomes of Medicare beneficiaries hospitalised with transient ischaemic attack and stratification using the ABCD2 score by Shah, Shreyansh, Liang, Li, Bhandary, Durgesh, Johansson, Saga, Smith, Eric E, Bhatt, Deepak L, Fonarow, Gregg C, Khan, Naeem D, Peterson, Eric, Bettger, Janet Prvu

“…BackgroundLong-term outcomes for Medicare beneficiaries hospitalised with transient ischaemic attack (TIA) and role of ABCD2 score in identifying high-risk…”
Get full text

Association of a P2Y12 Inhibitor Copayment Reduction Intervention With Persistence and Adherence With Other Secondary Prevention Medications: A Post Hoc Analysis of the ARTEMIS Cluster-Randomized Clinical Trial by Fanaroff, Alexander C, Peterson, Eric D, Kaltenbach, Lisa A, Cannon, Christopher P, Choudhry, Niteesh K, Henry, Timothy D, Anstrom, Kevin J, Cohen, David J, Fonseca, Eileen, Khan, Naeem D, Fonarow, Gregg C, Wang, Tracy Y

“…The Affordability and Real-World Antiplatelet Treatment Effectiveness After Myocardial Infarction Study (ARTEMIS) cluster-randomized trial found that copayment…”
Get more information

Clinically feasible stratification of 1-year to 3-year post-myocardial infarction risk by Horne, Benjamin D, Muhlestein, Joseph B, Bhandary, Durgesh, Hoetzer, Greta L, Khan, Naeem D, Bair, Tami L, Lappé, Donald L

“…ObjectivePost-myocardial infarction (MI) care is crucial to preventing recurrent major adverse cardiovascular events (MACE), but can be complicated to…”
Get full text

Effect of Medication Co-payment Vouchers on P2Y^sub 12^ Inhibitor Use and Major Adverse Cardiovascular Events Among Patients With Myocardial Infarction: The ARTEMIS Randomized Clinical Trial by Wang, Tracy Y, Kaltenbach, Lisa A, Cannon, Christopher P, Fonarow, Gregg C, Choudhry, Niteesh K, Henry, Timothy D, Cohen, David J, Bhandary, Durgesh, Khan, Naeem D, Anstrom, Kevin J, Peterson, Eric D

“…Importance Despite guideline recommendations, many patients discontinue P2Y12 inhibitor therapy earlier than the recommended 1 year after myocardial infarction…”
Get full text

Effect of Medication Co-payment Vouchers on P2Y 12 Inhibitor Use and Major Adverse Cardiovascular Events Among Patients With Myocardial Infarction: The ARTEMIS Randomized Clinical Trial by Wang, Tracy Y., Kaltenbach, Lisa A., Cannon, Christopher P., Fonarow, Gregg C., Choudhry, Niteesh K., Henry, Timothy D., Cohen, David J., Bhandary, Durgesh, Khan, Naeem D., Anstrom, Kevin J., Peterson, Eric D.

Get full text

Abstract 14907: Clinically Feasible Electronic Health Record Tool for Stratification of 1- to 3-Year Post-Myocardial Infarction Risk of Cardiovascular Events: The Intermountain Acute Coronary Syndromes Risk Scores by Horne, Benjamin D, Muhlestein, Joseph B, Bhandary, Durgesh, Hoetzer, Greta L, Khan, Naeem D, Bair, Tami L, Lappé, Donald L

“…BackgroundRandomized trials report that prolonged (>1 year) use of P2Y12 inhibitors with aspirin after myocardial infarction (MI) reduces stent thrombosis and…”
Get full text

Abstract 12443: Incident Heart Failure Risk After Acute Myocardial Infarction is Stratified by the Intermountain Major Adverse Cardiovascular Events (IMACE) Risk Scores by Horne, Benjamin D, Muhlestein, Joseph B, Bhandary, Durgesh, Kfoury, Abdallah G, Hoetzer, Greta L, Bair, Tami L, Khan, Naeem D, Lappé, Donald L

“…IntroductionPreviously, the Intermountain Mortality Risk Scores (IMRS) were created to predict all-cause mortality, but also predicted incident heart failure…”
Get full text

Abstract 12079: Initial Report From an Emergency-Department-Based Registry of NSTEMI Patients Given Upstream Advanced Oral Antiplatelet Therapy by Pollack, Charles V, Bhandary, Durgesh D, Frost, Alex, Peacock, W Frank, Diercks, Deborah B, Silber, Steven H, Rao, Sunil V, Bangalore, Sripal, Reicher, Barry, Burke, Lea M, DeRita, Renato, Khan, Naeem D

“…IntroductionThere are scant data on use of P2Y12 antagonist therapy upstream of diagnostic angiography (DA), especially when administered in the emergency…”
Get full text